Six weeks of treatment in a midstage clinical trial with a potential remyelination agent led to increases in a measure of optic nerve conduction in patients with acute optic neuritis, a condition often seen in conjunction with multiple sclerosis, the drug’s sponsor said.

In the placebo-controlled, 82-patient phase II RENEW trial, a per-protocol analysis showed that those receiving the anti-LINGO-1 monoclonal antibody experienced a 34% improvement in the recovery of optic nerve latency (P=0.0504), the study’s primary endpoint, according to a statement from Biogen Idec.

READ FULL ARTICLE Curated publisher From Medical Page Today